Business Context and Reporting Period
This Form 8-K is filed by Xenomics, Inc. (not Cardiff Oncology, Inc., as indicated in the metadata) for the reporting period of February 14, 2005. The filing discloses the entry into a material definitive agreement and the appointment of a principal officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed relates to executive compensation:
- Base Salary: $60,000 annually for the new Vice President-Controller.
- Stock Options: 75,000 incentive stock options with an exercise price of $2.50 per share.
- Vesting Schedule: 25,000 options vest annually over three years, commencing January 14, 2006.
Material Changes
The primary material change is the appointment of Bernard Denoyer as Vice President-Controller, effective February 14, 2005. Mr. Denoyer joins from Callisto Pharmaceuticals, Inc., where he served as Vice President, Finance since January 2004. He previously held CFO roles at META Group, Inc. and provided interim CFO services to various technology companies.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The agreement includes standard non-competition and non-solicitation provisions applicable to Mr. Denoyer during and after his employment term. The employment term is one year, automatically renewable for successive one-year periods unless written notice of non-renewal is provided.
Key Facts for Investor Verification
- Verify the registrant name is Xenomics, Inc., not Cardiff Oncology, Inc.
- Confirm the total equity dilution impact of the 75,000 options granted to Mr. Denoyer.
- Review the attached Exhibit 4.1 for specific terms regarding termination and severance not detailed in the summary.
- Assess the strategic fit of Mr. Denoyer's biotechnology and technology research background with Xenomics' current business model.